Teva intends to beg a brace of this steadfastness waiting further appeals. Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This manumit contains forward-looking statements, which rapid the tenor beliefs and expectations of management. Such statements are based on management's inclination beliefs and expectations and mean a million of known and unresearched risks and uncertainties that could cause our coming results, playing or achievements to different significantly from the results, fulfilment or achievements expressed or implied by such forward-looking statements.
Important factors that could cause or give to such differences comprehend risks relating to: our skill to successfully emerge and commercialize additional pharmaceutical Products, the introduction of competing generic equivalents, the immensity to which we may get U.S. exchange exclusivity for on the cards of our new generic Products and regulatory changes that may halt us from utilizing exclusivity periods, game from brand-name companies that are under increased arm to token generic Products, or competitors that look to delay the introduction of generic Products, the bumping of consolidation of our distributors and customers, the liability for sales of generic Products earlier to a final stick-to-it-iveness of outstanding patent litigation, including that relating to the generic versions of Allegra(R) , Neurontin(R), Lotrel(R) and Protonix(R), the stuff of contest on our innovative Products, especially Copaxone(R) sales, the change of pharmaceutical commerce order and pending legislation that could fake the pharmaceutical industry, the problem of predicting U.S. Food and Drug Administration, European Medicines Agency and Other regulatory evidence approvals, the regulatory situation and changes in the fettle policies and structures of various countries, our power to realize expected results though our innovative R&D efforts, our gift to successfully identify, consummate and desegregate acquisitions, including the 'til acquisition of Barr Pharmaceuticals Inc., aptitude exposure to effect liability claims to the extent not covered by insurance, dependence on the effectiveness of our patents and Other protections for innovative Products, significant operations worldwide that may be adversely specious by terrorism, administrative or unwasteful instability or big hostilities, fulfil interruptions or delays that could development from the complex manufacturing of our Products and our broad supply chain, environmental risks, fluctuations in currency, reciprocation and enlist rates, and Other factors that are discussed in this crack and in our Other filings with the U.S. Securities and Exchange Commission ("SEC").
(more...)
Related posts
